$24.98
-0.060%Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Senior Vice President of Operations
Compensation
$627,388
Senior Vice President, General Counsel & Corporate Secretary
Compensation
$738,221
During the last 12 months, insiders have purchased $220K and sold $157K worth of AVNS shares, resulting in $63K of net buying activity.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
13.8K
152.17K
-152K
-$152K
20.0K
219.50K
345
4.37K
+215K
+$215K
Blackford Gary
Director
$220K
Holbrook Kerr
Officer: Svp, Chief Commercial Officer
$152K
Hurley John Joseph
Officer: Principal Accounting Officer
$4K
Moderately bullish with $63K net buying. Insiders show cautious optimism through measured share purchases.
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
2 insider sellers vs. 1 buyers. More insiders selling than buying suggests cautious or negative sentiment.
AVNS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 12, 2026 | April 21, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 14, 2025 | April 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 15, 2024 | April 25, 2024 | 2024 | |
DEF 14A DEF 14A N/A | March 17, 2023 | March 17, 2023 | ||
DEF 14A DEF 14A 2022 N/A | March 18, 2022 | April 28, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 19, 2021 | April 29, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 16, 2020 | April 30, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 15, 2019 | April 25, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 09, 2018 | April 26, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 10, 2017 | April 27, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.